Bladder Cancer Diagnosis
Bladder Cancer Diagnosis
Diagnosing bladder cancer is unusual in that the diagnostic procedure is also the first treatment: the tumour is seen with a camera and removed with an instrument passed through the urethra in the same sitting. What the resection specimen then shows — the cell grade, and above all whether muscle was sampled and whether it was invaded — determines every decision that follows.
Cystoscopy
Cystoscopy is a direct examination of the inside of the bladder with a thin instrument passed through the urethra, and it is the test that settles the question. It takes minutes and is usually done under local anaesthesia; a flexible instrument is used for inspection, and a rigid one when treatment is expected in the same session.
Two upgrades to plain cystoscopy are worth knowing about. Blue-light or photodynamic cystoscopy instils a photosensitising agent into the bladder beforehand, so that tumours fluoresce under blue light. It finds flat lesions and small satellite tumours that white light misses — precisely the lesions most likely to be high-grade, and the ones whose detection changes the risk category. Narrow-band imaging achieves something similar by filtering the light rather than by using a drug.
The other test done alongside is urine cytology, in which cells shed into the urine are examined. Its behaviour is asymmetric: it is reasonably good at detecting high-grade and flat tumours and unreliable for low-grade ones, so a normal cytology does not exclude a low-grade tumour, and an abnormal one with a normal-looking bladder prompts a search rather than reassurance.
Transurethral resection of the bladder tumour
Transurethral resection of a bladder tumour (TURBT) is the decisive step of the diagnosis: it removes the tumour that can be seen and sends the specimen to the pathology department. The operation needs no incision in the abdomen — the instrument enters through the urethra, usually under general or spinal anaesthesia.
The most important contents of the resection report are not how large the tumour was, but three things:
- Grade — low grade or high grade (why it matters: see Grading: the other half of the decision, below).
- Depth of invasion — whether the tumour has grown into the muscle layer.
- Whether the specimen contains muscle — the precondition for judging the item above. If the pathology report does not mention muscle, a conclusion that the tumour is not muscle-invasive has nothing to rest on.
The third point deserves separate emphasis, because it is often overlooked. When a tumour is high grade, or no muscle was seen in the first resection specimen, the guidelines call for a second resection within a few weeks. That is not a sign the operation was done badly; it is a known, expected limitation: a first resection sometimes leaves tumour behind and sometimes understates the depth, and a second resection corrects both — and with that can change the direction of treatment. As a patient, the practical step is to ask the pathology department for a report that states explicitly whether the specimen contained muscle, and to understand the purpose if a second resection is recommended.
Imaging the urinary tract
Because the urothelium is continuous from the kidney to the urethra, imaging is directed at the whole tract and not only at the bladder. It answers two questions: how deep the tumour has grown, and whether there is another lesion on the same lining. Different examinations answer them:
- CT urography — the standard examination of the upper urinary tract: contrast is given intravenously and the excretory phase is scanned, imaging the renal pelvis, ureters and bladder together. It shows whether a synchronous upper-tract tumour is present, and whether the kidneys are obstructed.
- MRI of the bladder — used before a decision about cystectomy, because it distinguishes a tumour that has reached the muscle from one that has grown into the surrounding fat, and identifies involvement of adjacent organs. It resolves the layers of the bladder wall better than CT, which makes it particularly useful in judging whether a bladder-preserving plan is feasible.
- Ultrasound — convenient and radiation-free, and often the first examination when haematuria is investigated. It detects hydronephrosis and larger bladder tumours, but it cannot assess muscle invasion reliably and misses flat lesions, so an ultrasound report on its own will not support a treatment decision.
- CT of the chest and abdomen — for staging once muscle-invasive disease is known, to look for spread to lymph nodes, lungs or liver.
Bone imaging — where there is bone pain or a biochemical suspicion of skeletal spread.
Patients frequently arrive having had only an ultrasound or only a cystoscopy, and the file is then incomplete in a way that matters: cystoscopy without upper-tract imaging cannot exclude a second tumour above, and ultrasound without a resection cannot establish grade or depth. One further point is easily overlooked — imaging is best provided as the original images rather than as reports alone. A report usually states conclusions, whereas the route recommended afterwards, such as whether a bladder-preserving plan is feasible, often turns on detail the report does not record, such as the relationship of the tumour to each layer of the bladder wall. That is why images are more useful than text in a remote assessment.
Staging
Staging describes how deep the tumour has grown and how far it has spread, and it follows the AJCC 8th edition TNM system. In bladder cancer the most important dividing line is not between stage I and stage II but between non-muscle-invasive (Tis, Ta, T1) and muscle-invasive (T2 and above) disease, because the two sides of that line are treated in completely different directions:
- Ta — a papillary tumour confined to the lining, not extending into the layer beneath it.
- Tis — carcinoma in situ: flat, high-grade, confined to the lining, not projecting into the cavity, and easily missed under white light; it is the form most likely to progress.
- T1 — the tumour has reached the connective tissue layer beneath the lining but not the muscle.
- T2 — the tumour has reached the muscular wall, subdivided into T2a (superficial muscle) and T2b (deep muscle).
- T3 — it has grown through the muscle into the fat around the bladder.
- T4 — it involves adjacent structures such as the prostate, uterus, vagina, pelvic wall or abdominal wall.
- N and M — whether pelvic lymph nodes (N) or distant sites (M) are involved, the latter most often lymph nodes, bone, liver or lung.
Ta, Tis and T1 together make up non-muscle-invasive bladder cancer — about three-quarters of diagnoses — and T2 and above make up muscle-invasive disease. That single division, not the finer numbering, is what changes the treatment: non-muscle-invasive disease is managed through the urethra and by instilling drugs into the bladder, while muscle-invasive disease is managed by removing the bladder or by irradiating it with chemotherapy. Stage and risk category are not the same thing, however: the stage describes where the tumour has reached, while the risk category additionally takes account of grade, the number and size of the tumours, whether they recur, and whether carcinoma in situ is present — and those together determine how intensive the intravesical treatment and follow-up need to be. A complete assessment should give both, not a T stage alone.
The reporting of stage is therefore inseparable from the quality of the resection. If the specimen contains muscle, the distinction between T1 and T2 can be made; if it does not, the pathologist can report grade but cannot exclude muscle invasion, and the honest answer is that the stage is unknown until a second resection is performed.
Grading: the other half of the decision
Grading describes how abnormal the tumour cells look, and in bladder cancer it is deliberately simple — the modern WHO scheme groups urothelial tumours into low grade and high grade, with a separate category of papillary neoplasm of low malignant potential for lesions that are almost benign.
Grade matters because it predicts behaviour independently of depth. A low-grade tumour that has reached the connective tissue and a high-grade tumour at the same depth are not the same disease: the high-grade tumour is substantially more likely to progress to muscle invasion, and its presence is the usual reason cystectomy is discussed early rather than deferred. Grade is also what makes carcinoma in situ dangerous out of proportion to its size — it is high grade by definition, flat, and often invisible without blue light.
Two consequences for patients. A report that states only a stage without a grade is incomplete, and both should be asked for. And grade is assigned by a pathologist looking at tissue, which is why a resection rather than a urine test is required — cytology can suggest high grade but cannot assign it.
Turning the findings into a plan
Once the resection specimen, the cytology and the imaging are in hand, the plan follows from the risk group rather than from the stage number alone. The questions a written assessment should answer are these, and they are interdependent rather than separate:
Is the tumour non-muscle-invasive or muscle-invasive — and was muscle present in the specimen?
What is the grade, and is carcinoma in situ part of the picture?
Was the resection complete, and is a second resection needed — this is the step that most often changes the risk category
Is the upper urinary tract clear — this decides whether treatment and follow-up must cover the kidney and the ureter
Which intravesical regimen fits the risk group, and for how long?
If the disease is muscle-invasive: is the patient a candidate for cystectomy, and is a bladder-preserving plan open?
What is the surveillance schedule, and what would trigger a change of plan?
Two of those questions are the ones most often left unanswered at first consultation, and they are the ones that most affect what happens next. Whether a second resection is needed is decided by whether muscle was sampled and whether the tumour was high grade — and it is the step that most often changes the risk category. Whether cystectomy and bladder preservation are both genuinely open depends on tumour features and on fitness for surgery, and a plan that presents only one of them is not a complete assessment. A written assessment should therefore answer the questions as a set and state which findings would change the recommendation. Arranging the records so that they can be answered together is what a second-opinion review is for — a single reply to a file containing the resection pathology, the cytology and the imaging is more useful than answers to pieces sent separately.